logo-loader
viewAvacta Group PLC

Interest in Avacta’s Affimer technology continues to grow as biotech unveils latest research partnership

This time it is with OncoSec Medical, which wants to use its own gene delivery platform to deliver Avacta’s Affimers into tumour cells

cell in the body
Protein drugs such as Affimers can be delivered to a patient by injection or cells in the body can be made to make the protein if the DNA blueprint of the protein can be placed into the cells

The interest in Avacta Group PLC’s (LON:AVCT) Affimer technology continues to grow as the junior biotech announced another collaboration on Monday, this time with OncoSec Medical Inc (NASDAQ:ONCS).

Last week chief executive Alastair Smith said he had spoken with a lot of companies at a recent conference which were keen on teaming up with his firm.

Avacta is a pioneer of Affimer technology - small, engineered proteins that are capable of binding specific molecular targets, in a similar way to antibodies.

OncoSec, on the other hand, has developed a gene delivery technology called ImmunoPulse which it wants to use to deliver Affimers - including Avacta’s PD-L1 inhibitor - into tumour cells and other tissues.

The companies plan to then demonstrate the efficacy of the Affimers in a relevant in vivo tumour model.

‘Potentially very large opportunity’

“Avacta is receiving a lot of interest in the Affimer platform for gene delivery and this is the third collaboration in this hugely important area following our partnerships with Moderna Therapeutics and FIT Biotech,” said Smith.

“This is potentially a very large opportunity for Avacta and a successful outcome of the collaborative work with OncoSec would not only create the potential for the two companies to consider future co-developments but would also support Affimer licensing deals more widely in this rapidly growing field.”

Both Avacta and OncoSec will bear their own internal costs, while any third-party costs will be shared, although they are expected to be minimal.

Broker: ‘Avacta building momentum’

“Combining Avacta’s Affimers with OncoSec's gene delivery technology should create assets for co-development and/or licensing,” said finnCap analyst Mark Brewer.

“It illustrates the interest in gene delivery, given the potential to reduce development timelines compared with those for a conventional therapeutic protein.

“No change to forecasts or target price, but once again this illustrates the broadening utility of Affimers and the increasing interest shown by third-party pharma who see the potential of the Affimer platform.”

Shares nudged 1.2% higher to 67.3p on Monday morning.

--Updates for broker comment and share price--

Quick facts: Avacta Group PLC

Price: 16.5 GBX

AIM:AVCT
Market: AIM
Market Cap: £29.03 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Avacta Group PLC named herein, including the promotion by the Company of Avacta Group PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Avacta Group heading into 'crucial year' for its cancer therapeutics programmes

Proactive Research analyst Ed Stacey says Avacta (LON:AVCT) is preparing for a crucial year in its cancer therapeutics programmes in 2020, with an opportunity now identified for a targeted chemotherapy programme to enter clinical trials during the first half. Stacey says alongside the recent...

on 23/10/19

2 min read